Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.34 |
| ▸ | SRC | P12931 | 3/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670508 | 0.92 | HDAC6 (0.38) | HDAC6HDAC1HDAC8HDAC5SRC | |
| SCHEMBL32670494 | 0.92 | HDAC1 (0.36) | HDAC6HDAC1HDAC8HDAC5SRC | |
| SCHEMBL32670403 | 0.91 | HDAC6 (0.35) | HDAC6HDAC1HDAC8HDAC5SRC | |
| SCHEMBL30830344 | 0.89 | HDAC6 (0.37) | HDAC6HDAC1HDAC8HDAC5SRC | |
| SCHEMBL26961686 | 0.87 | FAAH (0.33) | HDAC6HDAC1HDAC8SRCIDH1 | |
| SCHEMBL29796898 | 0.87 | SCN10A (0.34) | HDAC6HDAC1HDAC8HDAC5SRC | |
| SCHEMBL26962037 | 0.87 | SCN10A (0.34) | HDAC6HDAC1HDAC8HDAC5SRC | |
| SCHEMBL29796828 | 0.85 | HDAC6 (0.38) | HDAC6HDAC1HDAC8HDAC5HDAC4 | |
| SCHEMBL26961865 | 0.85 | HDAC6 (0.38) | HDAC6HDAC1HDAC8HDAC5HDAC4 | |
| SCHEMBL29796770 | 0.84 | HDAC6 (0.37) | HDAC6HDAC1HDAC8HDAC5SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035364-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4568958-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024033388-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035364-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | SCN1B, SCN2B, SCN11A | HDAC6 460/4885HDAC1 298/4885HDAC8 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.